Non-Hodgkin Lymphoma (NHL)

Latest News

The data suggest BsAbs are safe and effective in many patients with relapsed or refractory LBCL following CAR T-cell therapy. | Image credit: jarun011 - stock.adobe.com
Early Relapse After CAR T-Cell Therapy Linked With Poor BsAb Outcomes in LBCL

May 23rd 2025

Elevated LDH and higher international prognostic index were also predictors of poor outcomes on bispecific antibodies, investigators found.

Overall, there were 36 factors identified as having a prognostic impact on at least 1 clinical outcome. | Image Credit: laszlo - stock.adobe.com
Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL

May 16th 2025

Q&A with Andrew Evens, DO
Collaboration Advances Lymphoma Care: Andrew Evens, DO

May 12th 2025

Andrew Evens, DO
Expanding Resources, Clinical Knowledge to Enhance AYA NHL Care: Andrew Evens, DO

May 2nd 2025

Multigenerational | Image Credit: © DisobeyArt-stock.adobe.com
DLBCL Outcomes Vary Sharply for Patients 80 Years and Older

April 16th 2025

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo